Publication: 2347

Publication: 2347

Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.

PubMed

DOI

Google Scholar

Citation:: J Gastrointest Cancer vol 38 (2-4) 87-94

Year:: 2007
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: Received

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 551
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:
Grants:: CA-25224, CA-35103, CA-35113, CA-35119, CA-35267, CA-35269, CA-35448, CA-37404, CA-45450, CA-52352, CA-60276, CA35431

Corr. Author:: Steven R Alberts
Authors:: Steven R Alberts Jonathan R Sande Nathan R Foster Fernando J Quevedo Robert R McWilliams John W Kugler Tom R Fitch Anthony J Jaslowski

Networks:

Study: NCCTG-N9943
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 1/2

Keywords:: Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Deoxycytidine, Female, Gallbladder Neoplasms, Glutamates, Guanine, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Pemetrexed, Prognosis, Survival Rate, Treatment Outcome